| 1 |
Almajidi YQ, M Kadhim M, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W, Ertas YN. Doxorubicin-loaded micelles in tumor cell specific chemotherapy. Environ Res 2023;:115722. [PMID: 36948284 DOI: 10.1016/j.envres.2023.115722] [Reference Citation Analysis]
|
| 2 |
Entezari M, Yousef Abad GG, Sedghi B, Ettehadi R, Asadi S, Beiranvand R, Haratian N, Karimian SS, Jebali A, Khorrami R, Zandieh MA, Saebfar H, Hushmandi K, Salimimoghadam S, Rashidi M, Taheriazam A, Hashemi M, Ertas YN. Gold nanostructure-mediated delivery of anticancer agents: Biomedical applications, reversing drug resistance, and stimuli-responsive nanocarriers. Environ Res 2023;225:115673. [PMID: 36906270 DOI: 10.1016/j.envres.2023.115673] [Reference Citation Analysis]
|
| 3 |
Gheytanchi E, Tajik F, Razmi M, Babashah S, Cho WCS, Tanha K, Sahlolbei M, Ghods R, Madjd Z. Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis. Cancer Cell Int 2023;23:10. [PMID: 36670440 DOI: 10.1186/s12935-023-02851-8] [Reference Citation Analysis]
|
| 4 |
Hashemi M, Mirzaei S, Zandieh MA, Rezaei S, Amirabbas Kakavand, Dehghanpour A, Esmaeili N, Ghahremanzade A, Saebfar H, Heidari H, Salimimoghadam S, Taheriazam A, Entezari M, Ahn KS. Long non-coding RNAs (lncRNAs) in hepatocellular carcinoma progression: Biological functions and new therapeutic targets. Prog Biophys Mol Biol 2023;177:207-28. [PMID: 36584761 DOI: 10.1016/j.pbiomolbio.2022.12.004] [Reference Citation Analysis]
|
| 5 |
Hashemi M, Hajimazdarany S, Mohan CD, Mohammadi M, Rezaei S, Olyaee Y, Goldoost Y, Ghorbani A, Mirmazloomi SR, Gholinia N, Kakavand A, Salimimoghadam S, Ertas YN, Rangappa KS, Taheriazam A, Entezari M. Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106535] [Reference Citation Analysis]
|
| 6 |
Sun P, Yang X. Hsa_circ_0097271 Knockdown Attenuates Osteosarcoma Progression via Regulating miR-640/MCAM Pathway. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/8084034] [Reference Citation Analysis]
|
